RG7795

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
RG7795
Legal status
Legal status
  • Investigational
Identifiers
CAS Number

RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B.[1] It is an orally-available prodrug of isatoribine,[2] that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011.[3] Its active metabolite is an [agonist]] of TLR7; activation of TLR7 causes secretion of endogenous type 1 interferons, which have antiviral activity.[2]

References[edit]

  1. ^ "RG 7795". AdisInsight. Retrieved 28 August 2017.
  2. ^ a b Funk, E; Kottilil, S; Gilliam, B; Talwani, R (14 May 2014). "Tickling the TLR7 to cure viral hepatitis". Journal of Translational Medicine. 12: 129. doi:10.1186/1479-5876-12-129. PMC 4039542. PMID 24884741.
  3. ^ "Inovio Goes It Alone on Hepatitis B Immunotherapy Vaccine as Roche Ends Collaboration". Genetic Engineering News. August 3, 2016.